Topline results released today from the RADIANCE II trial show the Paradise ultrasound renal denervation system significantly reduces daytime ambulatory systolic blood pressure compared with a sham procedure at 2 months in patients with mild to moderate uncontrolled hypertension.
The trial was conducted in 224 patients who were previously treated with up to two medications and were randomized while off medication at more than 60 centers in 8 countries. No further details or results were provided.
The pivotal RADIANCE II trial, required for FDA approval, is the third and largest randomized, sham-controlled study following positive results reported by RADIANCE-HTN SOLO and RADIANCE-HTN TRIO, ReCor Medical and its subsidiary Otsuka Medical Devices noted in the announcement.
The field of renal denervation fell out of favor after the largest trial in 535 patients, SYMPLICITY HTN-3, failed to show a significant reduction in systolic blood pressure at 6 months compared with sham control in resistant hypertension.
Lead Image: Science Photo Library/Getty Images
Medscape Medical News © 2022 WebMD, LLC
Send news tips to email@example.com.
Cite this: RADIANCE II: Positive Signal for Ultrasound Renal Denervation – Medscape – Jul 26, 2022.